How and where to order Bimatoprost (Latisse, Lumigan, Careprost) ophthalmic solution 0.03% 3 ml online:
LATISSE (BIMATOPROST) OPHTHALMIC SOLUTION 0.03%: WARNINGS (see "References")
Effects on Intraocular Pressure
Bimatoprost ophthalmic solution (Lumigan) lowers intraocular pressure (IOP) when instilled directly to the eye in patients with elevated IOP. In clinical trials, in patients with or without elevated IOP, Latisse lowered IOP, however, the magnitude of the reduction was not cause for clinical concern.
In ocular hypertension studies with Lumigan, it has been shown that exposure of the eye to more than one dose of bimatoprost daily may decrease the intraocular pressure lowering effect. In patients using Lumigan or other prostaglandin analogs for the treatment of elevated intraocular pressure, the concomitant use of Latisse (Bimatoprost) eye drops may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including Lumigan for IOP reduction should only use Latisse after consulting with their physician and should be monitored for changes to their intraocular pressure.
Increased iris pigmentation has occurred when the same formulation of bimatoprost ophthalmic solution (Lumigan) was instilled directly onto the eye. Although iridal pigmentation was not reported in clinical studies with Latisse (Bimatoprost) ophthalmic solution) 0.03%, patients should be advised about the potential for increased brown iris pigmentation which is likely to be permanent.
The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. The long term effects of increased pigmentation are not known. Iris color changes seen with administration of bimatoprost ophthalmic solution may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. Treatment with Latisse solution can be continued in patients who develop noticeably increased iris pigmentation.
Patients who receive treatment with Latisse (Bimatoprost) eye drops 0.03% should be informed of the possibility of increased pigmentation.
Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of bimatoprost in most patients.
Latisse prescribing information
Disclaimer: Please note, this website is not an online pharmacy, drugstore and related online pharma shop. It does not sell, supply or advertise any prescription and OTC drugs, medications, other goods and services. All reviews, links, lists, databases, texts, and other content on the website are provided free and only for informational and educational purposes. Medical content on this website, including drug names, indications, contraindication, side effects, categories, classifications, forms, doses, prices, other health and pharmaceutical information are taken only from trusted and authoritative professional sources (see "References"), reviewed and prepared by our licensed experts, content inspectors and editors.
You should always consult your doctor or other healthcare professional before using any medication. This website, our staff and support do not provide own medical instructions and advices.
All brands and trade names appearing on the website are registered trademarks of their respective companies.
Remember that buying drugs and medicines online is a responsibility only of customers, sellers and suppliers regarding existing legislation in their jurisdictions.
Share us in social media:
Copyright © 2014-2020 BimatoprostBuyOnline.com, a division of Pharma-Doctor.com pharmaceutical network. All rights reserved.
Home Page |
Cookies Policy |
Terms of Service |